Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed. Summary: Tocilizumab is a novel monoclonal antibody that ...

The US Food and Drug Administration (FDA) has granted approval for Celltrion's Avtozma (tocilizumab-anoh) in both intravenous and subcutaneous formulations as an Actemra biosimilar for treating ...

Tocilizumab and rituximab reduce relapse rates and disability progression in NMOSD, with tocilizumab provides extra benefits in MOGAD.

2012;12(3):319-333. The most recent biologic therapy to receive marketing approval, tocilizumab, was evaluated in a 24-week, randomized, placebo-controlled trial (RADIATE) of patients with RA who ...

Celltrion has secured marketing authorisation from the European Commission (EC) for Avtozma (CT-P47), a biosimilar to Chugai Pharmaceutical’s RoActemra (tocilizumab). The approval allows Avtozma ...

AVTOZMA® is Celltrion’s twelfth biosimilar to obtain marketing authorization in the European Union. Stay tuned to Big Molecule Watch for more regulatory updates on biosimilars.

The biosimilar of IL-6 inhibitor tocilizumab, called Tyenne (formerly MSB11456), has been approved for the same indications as Roche’s brand, including rheumatoid arthritis, systemic juvenile ...

Reason for decision Not eligible for Health Technology Evaluation guidance Further information Decision makers have concluded that this technology will not progress as a potential technology appraisal ...

INCHEON, SOUTH KOREA – Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma ® (CT-P47), a biosimilar referencing RoActemra ® (tocilizumab).